Keywords: avexa, enters, apricitabine, deal, novasep, australian, biotechnology

Avexa enters apricitabine deal with Novasep

Article | 26 February 2007

Australian biotechnology firm Avexa has signed a manufacturing agreement for the production of apricitabine, its nucleoside reverse transcriptase inhibitor for ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Novasep

Go to company listing